Robinhood Equity Token RHET
RHET is a security token that derives its value from secondary acquisition of securities of Robinhood Inc.
Interest Rank
This rank shows the popularity of this STO page among other STOs.
Rank
# 81
24H
0%
7D
88.9%
1M
0%
Description
RHET is a security token that derives its value from secondary acquisition of securities of Robinhood Inc. It gains value from the price appreciation of Robinhood Inc shares.
The RHET Token is essentially:
A fractional ownership stake in a special purpose fund with ownership in Robinhood Inc
A blockchain based security token, issued within a regulatory compliant framework.
The shares are held by an SPV, managed by a Syndicate Manager
The RHET Token is essentially:
A fractional ownership stake in a special purpose fund with ownership in Robinhood Inc
A blockchain based security token, issued within a regulatory compliant framework.
The shares are held by an SPV, managed by a Syndicate Manager
General information
Main sale ●Ended
Until January 12, 2019
Issuance platform:
The platform implements the technical and legal part of the release of the STO.
Legal
Company name:
Robinhood Inc.
Founded date:
August 2018
Asset
Asset class:
A group of securities that exhibits similar characteristics, behaves similarly in the marketplace and is subject to the same laws and regulations. The five main asset classes are equities (stocks), fixed income (bonds), cash equivalents (money market instruments), real estate, funds.
Token details
Symbol:
RHET
Financial information
Minimum goal:
Minimum goal for total funds raised in an STO.
$300K
Fundraising goal:
Maximum goal for total funds raised in an STO.
$1M
Other STOs
Sports Ledger
The first sports data analytics platform to leverage the power of Blockchain technology and Smart Contracts
Ended
7Pass
Investment vehicle spanning a spectrum of emerging investment opportunities in the cannabis sector
TBA
Rise
Invest in world-class A.I.-powered trading strategies that have beaten global markets since 2012.
Ended
Agenus
Our goal is to treat cancers with novel combinations
TBA